ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePediatric patients with gastrointestinal (GI) dysmotility have limited pharmacologic options due to questionable efficacy and/or safety profiles. The primary objective of this study was to assess the safety of azithromycin in pediatric patients for GI dysmotility. The secondary objective of this study was to evaluate the efficacy of azithromycin in treating GI dysmotility in pediatric patients.
methodsA retrospective cohort analysis was conducted from October 1, 2019, to September 30, 2023. Pediatric patients (18 years and younger) who received azithromycin specifically for GI dysmotility were included in the study. Safety endpoints assessed included description of known common and serious adverse events (ADEs) for azithromycin and corrected QT (QTc) interval exceeding 450 milliseconds (ms) using an electrocardiogram. Demographics, indications, dosing regimens, electrocardiographic data, treatment duration, clinical outcomes, and ADEs were assessed.
resultsForty-three patients met inclusion criteria. The cohort was predominantly composed of infants (0-2 years, 55.8%) and female (53.5%). Baseline electrocardiograms were conducted in 41.9% of patients, one of whom had a QTc interval exceeding 450 milliseconds. Median azithromycin dosing was 3 mg/kg/day with a maximum single dose of 300 mg. Treatment duration ranged from 7 days to over 4 years with a median of 56 days. ADEs were described in six patients and were minor in nature with most occurring within two weeks of therapy initiation. Symptom improvement was documented in 18 patients (41.9%).
conclusionsOral azithromycin may represent a safe and viable option in pediatric patients with GI dysmotility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.